Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder

被引:137
|
作者
Stampfer, DS [1 ]
Carpinito, GA
Rodriguez-Villanueva, J
Willsey, LW
Dinney, CP
Grossman, HB
Fritsche, HA
McDougal, WS
机构
[1] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA
[2] Boston Univ, Med Ctr, Dept Urol, Boston, MA 02215 USA
[3] Univ Texas, Md Anderson Canc Ctr, Dept Lab Sci, Houston, TX USA
[4] Univ Texas, Md Anderson Canc Ctr, Dept Urol, Houston, TX USA
关键词
bladder; carcinoma; transitional cell; bladder neoplasms; nuclear matrix; tumor markers; biological;
D O I
10.1016/S0022-5347(01)63930-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Urinary nuclear matrix protein (NMP22) was evaluated for detection of new and recurrent bladder tumors in patients with a history of transitional cell carcinoma. Our objective was to determine sensitivity and specificity of this marker for tumors of various stages and grades, as well as its use as an adjunct to or substitute for urinary cytology. Materials and Methods: A total of 231 patients with a history of transitional cell carcinoma provided 288 voided urine samples before cystoscopic examination at 1 of 3 institutions (53 patients were reevaluated at least once). Urine samples were assayed for NMP22 using the NMP22 Test Kit.dagger Select patients underwent biopsy with appropriate additional therapy. Voided urinary cytology was obtained in 200 cases. End points for determination of the absence and presence of tumor were negative cystoscopy and positive biopsy, respectively. A receiver operating characteristics curve was constructed to determine the optimal NMP22 threshold for detection of transitional cell carcinoma. For positive biopsies NMP22 values were also correlated with tumor stage and grade. Comparison to cytology was limited to patients with complete data. Results: There were 208 negative cystoscopies (158 with cytology) and 66 positive cystoscopies with biopsy (42 with cytology). Of the cases 14 were eliminated from statistical analysis due to incomplete data. Receiver operating characteristics curve interpretation determined that 6.4 units per mi. was an optimal reference value for detection of transitional cell carcinoma in this patient group. Sensitivity and specificity for all pathological groupings was 68 and 80%, respectively. When compared to cytology the sensitivities of NMP22 and cytology were 67 versus 31 or 40% (depending on the definition of positive cytology). Conclusions: NMP22 values represented significant improvement over urinary cytology for detection of transitional cell carcinoma. The sensitivity of NMP22 for detection of transitional cell carcinoma in bladder cancer patients was as much as twice that of cytology when a reference value of 6.4 units per mi. was used. NMP22 analysis was less costly than cytology and operator independent. While NMP22 has previously been shown to be a strong predictor of recurrence after tumor resection, it is an effective and sensitive screening test for detecting tumors in patients with transitional cell carcinoma.
引用
收藏
页码:394 / 398
页数:5
相关论文
共 50 条
  • [1] Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder
    Sawczuk, IS
    Bagiella, E
    Sawczuk, AT
    Yun, EJ
    CANCER DETECTION AND PREVENTION, 2000, 24 (04): : 364 - 368
  • [2] Screening and monitoring for bladder cancer: Refining the use of NMP22
    Ponsky, LE
    Sharma, S
    Pandrangi, L
    Kedia, S
    Nelson, D
    Agarwal, A
    Zippe, CD
    JOURNAL OF UROLOGY, 2001, 166 (01) : 75 - 78
  • [3] Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transtional cell carcinoma of the bladder
    Menendez, V
    Filella, X
    Alcover, JA
    Molina, R
    Mallafre, JM
    Ballesta, AM
    Talbot-Wright, R
    ANTICANCER RESEARCH, 2000, 20 (2B) : 1169 - 1172
  • [4] BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder
    Casetta, G
    Gontero, P
    Zitella, A
    Pelucelli, G
    Formiconi, A
    Priolo, G
    Martinasso, G
    Mengozzi, G
    Aimo, G
    Viberti, L
    Tizzani, A
    UROLOGIA INTERNATIONALIS, 2000, 65 (02) : 100 - 105
  • [5] Evaluation of nuclear matrix protein 22 (NMP22) as a tumor marker in the detection of bladder cancer
    Öge Ö.
    Atsü N.
    Kendi S.
    Özen H.
    International Urology and Nephrology, 2001, 32 (3) : 367 - 370
  • [6] Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment
    Soloway, MS
    Briggman, JV
    Carpinito, GA
    Chodak, GW
    Church, PA
    Lamm, DL
    Lange, P
    Messing, E
    Pasciak, RM
    Reservitz, GB
    Rukstalis, DB
    Sarosdy, MF
    Stadler, WM
    Thiel, RP
    Hayden, CL
    JOURNAL OF UROLOGY, 1996, 156 (02) : 363 - 367
  • [7] NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer
    Zippe, C
    Pandrangi, L
    Agarwal, A
    JOURNAL OF UROLOGY, 1999, 161 (01) : 62 - 65
  • [8] Patients with a negative cystoscopy and negative Nmp22® Bladderchek® test are at low risk of missed transitional cell carcinoma of the bladder: a prospective evaluation
    Terrell, John D.
    Elias, Keren J.
    Sagalowsky, Arthur I.
    Lotan, Yair
    INTERNATIONAL BRAZ J UROL, 2011, 37 (06): : 706 - 711
  • [9] Comparison of urinary telomerase, CD44, and NMP22 assays for detection of bladder squamous cell carcinoma
    Al-Delaimy, Wael K.
    Awadalla, Amira
    El-Assmy, Ahmed
    Abol-Enein, Hassan
    Shokeir, Ahmed
    CURRENT UROLOGY, 2022, 16 (03) : 154 - 159
  • [10] Detection of Recurrent Bladder Cancer NMP22 Test or Urine Cytology?
    Hosseini, Jalil
    Golshan, Ali Reza
    Mazloomfard, Mohammad Mohsen
    Mehrsai, Abdolrasoul
    Zargar, Mohammad Ali
    Ayati, Mohsen
    Shakeri, Saeed
    Jasemi, Majid
    Kabiri, Mahmoud
    UROLOGY JOURNAL, 2012, 9 (01) : 367 - 372